CI Investments Inc
NTLA icon

CI Investments Inc’s Intellia Therapeutics NTLA Stock Holding History

CI Investments Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,953
Closed -$64K – 1327
2025
Q1 		$64K Sell
8,953
-41
-0.5% -$414 ﹤0.01% 1006
2024
Q4 		$105K Buy
8,994
+4,122
+85% +$64.3K ﹤0.01% 927
2024
Q3 		$100K Buy
4,872
+37
+0.8% +$853 ﹤0.01% 856
2024
Q2 		$108K Buy
4,835
+997
+26% +$23.7K ﹤0.01% 794
2024
Q1 		$106K Buy
3,838
+3
+0.1% +$83 ﹤0.01% 881
2023
Q4 		$117K Buy
3,835
+1,204
+46% +$34.6K ﹤0.01% 798
2023
Q3 		$83K Sell
2,631
-79
-3% -$3.06K ﹤0.01% 863
2023
Q2 		$111K Buy
2,710
+340
+14% +$13.8K ﹤0.01% 762
2023
Q1 		$88K Sell
2,370
-30
-1% -$1.18K ﹤0.01% 769
2022
Q4 		$84K Buy
2,400
+2,011
+517% +$95.6K ﹤0.01% 796
2022
Q3 		$22K Sell
389
-28
-7% -$1.74K ﹤0.01% 1017
2022
Q2 		$22K Sell
417
-147
-26% -$7.46K ﹤0.01% 961
2022
Q1 		$41K Buy
564
+207
+58% +$17.5K ﹤0.01% 984
2021
Q4 		$42K Buy
357
+70
+24% +$8.77K ﹤0.01% 1024
2021
Q3 		$39K Buy
+287
New +$43.5K ﹤0.01% 1002

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CI Investments Inc's NTLA Position: Q2 2025 in Review

CI Investments Inc sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 8,953 shares — an estimated $64K sold.

CI Investments Inc first reported a position in NTLA in Q3 2021 and held it in 15 quarters. The position peaked at $117K in Q4 2023. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • CI Investments Inc reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CI Investments Inc sold 8,953 Intellia Therapeutics shares in Q2 2025, an estimated $64K.
  • CI Investments Inc first reported a position in Intellia Therapeutics in Q3 2021 and held it in 15 quarters.
  • CI Investments Inc's Intellia Therapeutics position peaked at $117K in Q4 2023.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on CI Investments Inc's 13F filing for Q2 2025, filed 12 Aug 2025.